RecruitingPhase 3NCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Sponsor: Eli Lilly and Company
Media, PA · West Chester, PA · +78 more sites